Description
It is our pleasure to present to you, on behalf of the International Psychogeriatric Association (IPA), this new webinar: Transcranial Magnetic Stimulation (TMS): Applications in Older Adults.
Transcranial magnetic stimulation (TMS) is a non-invasive brain stimulation (NIBS) therapy that uses magnetic pulses applied to the scalp to stimulate specific target areas of the brain to increase cortical excitability. TMS is approved by the US Food and Drug Administration (FDA) for treatment-resistant major depression, and is also currently being investigated for other psychiatric, neuropsychiatric and neurologic conditions. An exciting application of TMS in older adults is cognitive impairment and evidence thus far suggests therapeutic benefits.
In this webinar, participants will gain an understanding of TMS as a treatment modality, learn evidence for its use for depression in older adults, and review relevant data on the effect on cognitive functioning in older adults.
As with all programs in the IPA Webinar Series, this presentation is intended as an educational event on topics that are timely and relevant to the field of mental health for older adults.
Prof. Myrra Vernooij-Dassen, PhD
Chair, IPA Webinar Series
Wednesday, 12 January 2022
Program & Presenters:
|
Opening Remarks & Moderator:
Professor Myrra Vernooij-Dassen, PhD Radboud University Nijmegen Medical Centre Chair, IPA Webinar Task Force The Netherlands |
|
Presentation: Advances in rTMS for the Treatment of Late-Life
Depression Dr. Daniel M. BlumbergerDirector and Chair, Temerty Centre for Therapeutic Brain Intervention, CAMH Professor, Department of Psychiatry, University of Toronto Canada |
 |
Presentation: TMS in Mild Cognitive
Impairment and Alzheimer’s Disease Simon Kung, MD Associate Professor of Psychiatry Vice Chair for Research Department of Psychiatry and Psychology Mayo ClinicUnited States |
Program Organizers:
|
|
|
|
|
Prof Myrra Vernooij-Dassen, PhD
Radboud University Nijmegen Medical Centre Chair, IPA Webinar Task Force The Netherlands |
Robert Madan MD FRCPC
Deputy Chief of Staff, Baycrest, Toronto, Canada |
Prof Maria I. Lapid, MD
Professor of Psychiatry Mayo Clinic, Rochester, MN, United States |
Contributors
-
Prof. Daniel Blumberger (Canada)
Dr. Daniel Blumberger is a Clinician Scientist in the Campbell Family Mental Health Research Institute at the Centre for Addiction and Mental Health (CAMH) at University of Toronto. He is the Medical Head and Co-Director of the Temerty Centre for Therapeutic Brain Intervention at CAMH. He is a subspecialist in geriatric psychiatry and also heads the Late-Life Mood Disorders Clinic. Dr. Blumberger’s research focuses on the use of brain stimulation therapies for refractory psychiatric disorders. His main research focuses on clinical intervention trials of novel treatments, and understanding the neurophysiology of treatment-resistant depression across the lifespan. His research has been funded by the Canadian Institutes of Health Research, National Institute of Health, Brain Canada, Weston Brain Institute, Brain and Behavior Research Foundation, and Patient- Centered Outcomes Research Institute.
-
Dr. Simon Kung (United States)
Dr. Simon Kung is an Associate Professor of Psychiatry and Vice-Chair of Research at the Mayo Clinic Department of Psychiatry and Psychology in Rochester, Minnesota.He completed his medical school and residency at Mayo Clinic.He is the medical director for the inpatient Mood Disorders Unit, clinical director of the Transcranial Magnetic Stimulation (TMS) program, and co-director of the Ketamine Clinic.His main areas of interest are treatment-resistant depression (unipolar and bipolar), brain stimulation (electroconvulsive therapy [ECT] and TMS), ketamine for depression, and applications of pharmacogenetic testing.